The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2019 | Combining checkpoint inhibitors with chemotherapy for NSCLC
Marina Garassino, MD, of National Cancer Institute of Milan, Milan, Italy, discusses the combined use of chemotherapy and immunotherapy for treating non-small cell lung cancer (NSCLC). Speaking at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Dr Garassino reports that identifying the clinical characteristics that differentiate between different NSCLC patient groups will help decide whether single agent therapy or combined therapy would be most appropriate for them.
